Connect with us:

Back

Clinical Trials

In addition to staying on top of the latest advances in veterinary medicine—our hospitals work together to develop them. Our doctors collaborate on clinical trials, always pushing the boundaries of what can be achieved in protecting the health and quality of life of the animals we all love.

Our network of hospitals appeals to sponsors seeking the benefits of multi-location opportunities. Smooth rollout of clinical trials and reliable communication throughout their implementation come naturally in our culture of teamwork.

Participating in clinical trials keeps our family of hospitals at the forefront of medical advancements, and attracts top specialists with a desire to grow and maximize their contributions throughout their careers.

Cardiology

Dr. Katie Pesce

Red Bank Veterinary Hospitals - Tinton Falls

To evaluate the relevance of history and presentation in the evaluation of chronic valve disease in small breed dogs.

Dr. Carl Sammarco

Red Bank Veterinary Hospitals - Tinton Falls

This study aims to collect data on procedural technique of the corrective surgery.

Dr. Carl Sammarco

Red Bank Veterinary Hospitals - Tinton Falls

This study aims to collect data on procedural technique of the corrective surgery.

Clinical Nutrition

Dr. Martha Cline

Red Bank Veterinary Hospitals - Tinton Falls

The primary aim of the study is to assess the clinical responses of cats with naturally occurring mild to moderate chronic enteropathy when fed different types of dry kibble diets.

Dr. Martha Cline

Red Bank Veterinary Hospitals - Tinton Falls

The primary aim of the study is to assess the clinical responses of cats with naturally occurring mild to moderate chronic enteropathy when fed different types of dry kibble diets. As part of this study, three visits to Red Bank Veterinary Hospital in Tinton Falls are required for the patient.

Owners must be willing to weigh the cat’s food daily for the entire 12 weeks. The owner will be required to fill out some screening paperwork before making the appointment, as well as, complete a daily log of their cat’s habits for the duration of the study. The majority of the study is at no cost to the client.

Dermatology

INTERNAL MEDICINE

Dr. Elizabeth Orcutt

Red Bank Veterinary Hospital, Tinton Falls, NJ

Our project aims to define biomarkers of severe primary ITP and identify genetic susceptibility loci implicated in loss of self-tolerance. Our first objective is to complete the GWAS with newly accrued ITP cases in a prospective, multi-institutional cohort study.

These analyses will determine whether CD226, a candidate disease gene within the trait locus, plays a role in ITP pathogenesis and allow us to determine whether CD226 polymorphisms influence the number or function of immunomodulatory T regulatory (Treg) cells. Our second objective is to identify ITP severity predictors.

Together, our genotyping and phenotyping strategy will lead to individualized, targeted patient management.

Neurology

Dr. Chelsie Estey

Animal Emergency & Specialty Center

The aim of this study is to assess the effect of cannabinoids on seizure frequency in poorly controlled epileptic dogs.

Oncology

Dr. Jennifer McDaniel

Veterinary Care Center, CT

This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC). The trial involves one-time procedure administered directly into the bladder using a urinary catheter. Dogs may receive a second infusion one month after enrollment if warranted.  The infusion will be administered under sedation or general anesthesia.

There is no placebo in this trial.  All Owners will be required to complete quality of life surveys, collect a daily urine sample for visual analysis, and record the urine collection results in a provided journal. Medications targeted at the treatment of TCC-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.

Dr. Jennifer McDaniel

Veterinary Care Center, CT

The purpose of this trial is to evaluate the safety and preliminary efficacy of a novel vaccine in companion dogs diagnosed with oral melanoma. A tumor-specific antigen (tyrosinase) carried by a FDA-approved bioengineered viral vector (AdenoAssociated Virus; AAV) is injected intramuscularly into the quadriceps muscle of the rear leg. In addition, the tyrosinase antigen is currently used as a target for an anti-cancer vaccine in humans and dogs.

Dr. Jennifer McDaniel

Veterinary Care Center, CT

TANOVEA®-CA1 (rabacfosadine for injection) is the first and only FDA conditionally approved drug for the treatment of lymphoma in dogs.  This pivotal study is intended to provide the data to demonstrate substantial evidence of effectiveness as well as additional safety information in support of full FDA approval.

VC-014 is a randomized, multi-center, double-blinded, placebo-controlled study evaluating TANOVEA®-CA1 (rabacfosadine for injection) administered every three weeks for up to five treatments in dogs with lymphoma (either previously treated or untreated).

Dr. Jaclyn Renner

Charleston Veterinary Referral Center

This study involves a type of immunotherapy which utilizes an autologous cancer cell vaccine (custom made using the patient’s own cancer cells), collection of the patient’s T cells, expansion and activation of those T cells outside the body, and then infusion of the autologous activated T cells back into patient with the intent to initiate immune responses that lead to high levels of cancer cell killing of the micrometastases following surgical resection of the primary cancer.

Dr. Jennifer McDaniel

The Veterinary Care Center - (CT)

This trial is evaluating a cancer vaccine strategy for EGFR

and/or HER2 bearing tumors in dogs.

Dr. Michelle Morges | Red Bank Veterinary Hospitals - Tinton Falls 

Dr. Jennifer McDaniel | Veterinary Care Center, CT.

The primary objective of this study is to determine the maximum tolerated dose, doe-limiting toxicities, safe starting dose, and pharmacodynamic effect of  TANOVEA in cats with lymphoma, lymphoid leukemia or multiple myeloma/plasma cell tumor.

Dr. Jennifer McDaniel

Veterinary Care Center, CT.

One Health discovers tumor mutations at a DNA level to provide veterinarians with personalized cancer treatments for each dog’s unique cancer. Since cancer is a disease of genetic mutations, it is critical to understand the underlying mutations driving your dog’s cancer to have the most informed treatment path.

This is a pilot study.

Dr. Michelle Morges

Red Bank Veterinary Hospitals - Tinton Falls 

To determine the efficacy and safety of alternating TANOVEA-CA1 and Doxorubicin treatments against multicentric lymphoma in previously untreated dogs.

Surgery

Dr. Garrett Davis & Dr. Jason Tarricone

Red Bank Veterinary Hospitals, Tinton Falls, NJ

The objectives of this study will be to assess client specific outcomes regarding pain relief for 4 weeks post-tibial plateau leveling osteotomy surgery; use objective quantitative forcemat analysis at weeks 0, 2 & 4; and assess serum chemistry for organ function and markers of chronic inflammation.

Dr. Brian Beale

Gulf Coast Veterinary Specialists

Marine based fatty acid compound and meloxicam in treatment of canine osteoarthritis: a randomized placebo controlled trial.

Dr. Jill Sammarco

Red Bank Veterinary Hospitals - Tinton Falls 

The aim of this study is to evaluate the client perception of quality of life improvement in Labrador Retrievers with laryngeal paralysis (LP given doxepin for one month compared to dogs given placebo.